Reference entry · Ghrelin mimetic hexapeptide
GHRP-2
Also known as: Pralmorelin · Growth hormone releasing peptide-2
- Class
- Ghrelin mimetic hexapeptide
- Size
- 6 amino acids
- Primary targets (literature)
- GHS-R / ghrelin receptor
- Regulatory context
- Not FDA-approved. Pralmorelin development did not yield a standalone approved product in major jurisdictions.
Overview
GHRP-2 is a first-generation growth hormone releasing peptide characterized in 1990s secretagogue research. It remains a reference compound in comparative GH-axis pharmacology literature.
Mechanism in research literature
Potent GHS-R agonism stimulates GH release with a hormonal side-effect profile that motivated development of more selective later-generation secretagogues like ipamorelin.
Common research focus areas
- Reference standard in secretagogue comparisons
- GH, cortisol, and prolactin response literature
- 1990s human pharmacology characterization
- Hexapeptide identity and purity
Full literature roundup
Read the cited research summary
A classic growth hormone releasing peptide with decades of GH-axis research. Literature summary, limitations, and material evaluation.
GHRP-2 research roundup · 5 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.